DICHLORPHENAMIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C6H6Cl2N2O4S2
Molecular Weight	305.159
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NS(=O)(=O)C1=CC(=C(Cl)C(Cl)=C1)S(N)(=O)=O

InChI

InChIKey=GJQPMPFPNINLKP-UHFFFAOYSA-N

InChI=1S/C6H6Cl2N2O4S2/c7-4-1-3(15(9,11)12)2-5(6(4)8)16(10,13)14/h1-2H,(H2,9,11,12)(H2,10,13,14)

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/011366s030lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.urmc.rochester.edu/news/story/4461/new-drug-for-periodic-paralysis-has-roots-in-urmc-research.aspx

Diclorphenamide, a carbonic anhydrase inhibitor, was initially developed for the treatment of glaucome, however, now it is used for patients suffering from primary hypokalemic and hyperkalemic periodic paralysis. The exact mechanism of diclorphenamide in periodic paralysis is unknown.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Carbonic anhydrase 6 Target ID: CHEMBL2095180 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/011366s030lbl.pdf	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Primary hyperkalemic periodic paralysis 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/011366s030lbl.pdf	Primary		Approved 8429	KEVEYIS Approved Use Keveyis is an oral carbonic anhydrase inhibitor indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants. Launch Date -3.61238397E11
Primary hypokalemic periodic paralysis 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/011366s030lbl.pdf	Primary		Approved 8429	KEVEYIS Approved Use Keveyis is an oral carbonic anhydrase inhibitor indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants. Launch Date -3.61324806E11

C_max

Value	Dose	Co-administered	Analyte	Population
3030 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/29762909	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		DICHLORPHENAMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
66456 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/29762909	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		DICHLORPHENAMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
41 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/29762909	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		DICHLORPHENAMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
12% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf			DICHLORPHENAMIDE plasma	Homo sapiens

Doses

Dose	Population	Adverse events
400 mg 2 times / day multiple, oral Highest studied dose Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29762909	healthy, 38.1±12.1 n = 6 Health Status: healthy Age Group: 38.1±12.1 Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/29762909	Disc. AE: Hypokalemia, Weight loss... AEs leading to discontinuation/dose reduction: Hypokalemia (mild, 83.3%) Weight loss (16.7%) Itchy throat (16.7%) Tachycardia (16.7%) Gait instability (moderate, 16.7%) Toothache (moderate, 16.7%) Sources: https://pubmed.ncbi.nlm.nih.gov/29762909
200 mg 1 times / day multiple, oral (total daily dose) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2d4d6a8e-3122-4b91-b46a-5708e60ea5c1&type=display	unhealthy Health Status: unhealthy Condition: Primary hyperkalemic periodic paralysis\|Primary hypokalemic periodic paralysis Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2d4d6a8e-3122-4b91-b46a-5708e60ea5c1&type=display	Disc. AE: Hypersensitivity, Hypokalemia... AEs leading to discontinuation/dose reduction: Hypersensitivity Hypokalemia Metabolic acidosis Fall Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2d4d6a8e-3122-4b91-b46a-5708e60ea5c1&type=display

AEs

AE	Significance	Dose	Population
Itchy throat	16.7% Disc. AE	400 mg 2 times / day multiple, oral Highest studied dose Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29762909	healthy, 38.1±12.1 n = 6 Health Status: healthy Age Group: 38.1±12.1 Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/29762909
Tachycardia	16.7% Disc. AE	400 mg 2 times / day multiple, oral Highest studied dose Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29762909	healthy, 38.1±12.1 n = 6 Health Status: healthy Age Group: 38.1±12.1 Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/29762909
Weight loss	16.7% Disc. AE	400 mg 2 times / day multiple, oral Highest studied dose Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29762909	healthy, 38.1±12.1 n = 6 Health Status: healthy Age Group: 38.1±12.1 Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/29762909
Hypokalemia	mild, 83.3% Disc. AE	400 mg 2 times / day multiple, oral Highest studied dose Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29762909	healthy, 38.1±12.1 n = 6 Health Status: healthy Age Group: 38.1±12.1 Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/29762909
Gait instability	moderate, 16.7% Disc. AE	400 mg 2 times / day multiple, oral Highest studied dose Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29762909	healthy, 38.1±12.1 n = 6 Health Status: healthy Age Group: 38.1±12.1 Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/29762909
Toothache	moderate, 16.7% Disc. AE	400 mg 2 times / day multiple, oral Highest studied dose Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29762909	healthy, 38.1±12.1 n = 6 Health Status: healthy Age Group: 38.1±12.1 Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/29762909
Fall	Disc. AE	200 mg 1 times / day multiple, oral (total daily dose) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2d4d6a8e-3122-4b91-b46a-5708e60ea5c1&type=display	unhealthy Health Status: unhealthy Condition: Primary hyperkalemic periodic paralysis\|Primary hypokalemic periodic paralysis Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2d4d6a8e-3122-4b91-b46a-5708e60ea5c1&type=display
Hypersensitivity	Disc. AE	200 mg 1 times / day multiple, oral (total daily dose) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2d4d6a8e-3122-4b91-b46a-5708e60ea5c1&type=display	unhealthy Health Status: unhealthy Condition: Primary hyperkalemic periodic paralysis\|Primary hypokalemic periodic paralysis Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2d4d6a8e-3122-4b91-b46a-5708e60ea5c1&type=display
Hypokalemia	Disc. AE	200 mg 1 times / day multiple, oral (total daily dose) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2d4d6a8e-3122-4b91-b46a-5708e60ea5c1&type=display	unhealthy Health Status: unhealthy Condition: Primary hyperkalemic periodic paralysis\|Primary hypokalemic periodic paralysis Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2d4d6a8e-3122-4b91-b46a-5708e60ea5c1&type=display
Metabolic acidosis	Disc. AE	200 mg 1 times / day multiple, oral (total daily dose) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2d4d6a8e-3122-4b91-b46a-5708e60ea5c1&type=display	unhealthy Health Status: unhealthy Condition: Primary hyperkalemic periodic paralysis\|Primary hypokalemic periodic paralysis Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2d4d6a8e-3122-4b91-b46a-5708e60ea5c1&type=display

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737 inhibitor 1587 inducer 781	substrate 1037 inhibitor 1767	substrate 1217 inhibitor 1852

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OAT1 599 CYP1A2 1524 CYP2B6 810 CYP2C8 911 CYP2C19 1478 P-gp 1461 BCRP 699 OATP1B1 788 OATP1B3 706 OAT2 145 OAT4 146 OCT1 512 OCT2 647 MATE1 306 MATE2 263 OAT3 642	OAT1 326 OAT3 339 CYP1A2 1054 CYP2B6 664 CYP2C8 693 CYP2C19 991 P-gp 1537 BCRP 561 OATP1B1 406 OATP1B3 350 OAT2 115 OAT4 78 OCT1 327 OCT2 355 MATE1 135 MATE2 96	CYP1A2 701 CYP2B6 547

Drug as perpetrator

Target	Modality	Activity
BCRP 773	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
CYP1A2 1692	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
CYP2B6 1001	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
CYP2B6 1001	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
CYP2C8 965	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
CYP3A4 1925	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
CYP3A4 1925	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
MATE1 308	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
MATE2 263	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
OAT2 147	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
OAT3 644	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
OAT4 146	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
OATP1B1 803	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
OATP1B3 715	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
OCT1 543	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
OCT2 648	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
P-gp 1650	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
OAT1 603	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 5.0	yes

Drug as victim

Target	Modality	Activity
BCRP 561	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
CYP1A2 1054	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 8.0	no
CYP2B6 664	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 8.0	no
CYP2C19 991	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 8.0	no
CYP2C8 693	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 8.0	no
CYP2C9 1037	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 8.0	no
CYP2D6 1217	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 8.0	no
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 8.0	no
MATE1 135	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
MATE2 96	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
OAT2 115	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
OAT4 78	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
OATP1B1 406	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
OATP1B3 350	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
OCT1 327	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
OCT2 355	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
P-gp 1537	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 9.0	no
OAT1 326	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 6.0	yes
OAT3 339	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf Page: 6.0	yes

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY116256	https://www.001chemical.com/chem/120-97-8
3B Scientific (Wuhan) Corp	3B3-059238	http://www.3bsc.com/index/pro_info.php?id=98059
AA Blocks	AA000PYI	https://www.aablocks.com/goods/Goods/detail?id=AA000PYI
AHH Chemical co.,ltd	MR-1005428	http://www.ahhchemical.com/product/MR-1005428.html
Aaron Chemicals	AR000QQA	http://www.aaronchem.com/120-97-8
AbMole Bioscience	M3421	http://www.abmole.com/products/dichlorphenamide.html
Acadechem	ACDS-033119	http://www.acadechemical.com/product/107818
Achemtek	0104-042128	http://www.achemtek.com/120-97-8
Adooq BioScience	A10303	https://www.adooq.com/diclofenamide.html
Alfa Chemistry	AP120978	https://reagents.alfa-chemistry.com/product/dichlorphenamide-cas-120-97-8-2745.html
Alfa Chemistry	ACM120978	https://www.alfa-chemistry.com/dichlorphenamide-cas-120-97-8-item-285105.htm
Ambeed	A201176	https://www.ambeed.com/products/120-97-8.html
Angel Pharmatech	AG193544	http://www.angelpharmatech.com/120-97-8.html
ApexBio Technology	A8408	http://www.apexbt.com/dichlorphenamide.html
BLD Pharm	BD124384	http://www.bldpharm.com/products/120-97-8.html
BioChemPartner	BCP22591	http://www.biochempartner.com/120-97-8-BCP22591
BioCrick	BCC3761	http://www.biocrick.com/Dichlorphenamide-BCC3761.html
BioSynth	W-108466	https://www.biosynth.com/en/products/life-science/other-biochemicals/products/W-108466.html
Boerchem	BC221062	http://www.boerchem.com/?product_37432.html
CSNpharm	CSN10791	https://www.csnpharm.com/products/dichlorphenamide.html
Capot Chemical	22279	http://www.capotchem.com/en/22279.htm
Capot Chemical	PubChem22279	http://www.capotchem.com/en/22279.htm
Chem Scene	CS-2491	http://www.chemscene.com/120-97-8.html
ChemMol	44006581	http://www.chemmol.com/chemmol/44006581.html
ChemMol	49426554	http://www.chemmol.com/chemmol/49426554.html
Chemenu	CM110408	http://www.chemenu.com/products/CM110408
Chemspace	CSSB00000058644	https://chem-space.com/CSSB00000058644
Clearsynth	CS-O-00248	http://www.clearsynth.com/en/CSO00248.html
Clearsynth	CS-EB-00649	https://www.clearsynth.com/en/CSEB00649.html
Clearsynth	CS-ER-00637	https://www.clearsynth.com/en/CSER00637.html
DC Chemicals	DCAPI1032	http://www.dcchemicals.com//product_show-Dichlorphenamide_Diclofenamide_.html
Excenen	EX-A1311	http://www.excenen.com/searchresultlist.php?id=120-97-8
Finetech	FT-0648264	http://www.finetechnology-ind.com/prod/detail/pub/120-97-8.html
Hairui	HR123582	http://www.hairuichem.com/en/product/120-97-8.html
LGC Standards	LGCFOR1795.00	https://www.lgcstandards.com/US/en/p/LGCFOR1795.00
LGC Standards	MM1795.00	https://www.lgcstandards.com/US/en/p/MM1795.00
Lab Network	LN01268499	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01268499
Matrix Scientific	144312	https://www.matrixscientific.com/144312.html
MedChem Express	HY-B0397	https://www.medchemexpress.com/Dichlorphenamide.html
Molcore	MC116256	https://www.molcore.com/product/120-97-8
MuseChem	I000784	https://www.musechem.com/product/I000784.html
OChem	12091	http://www.ocheminc.com/index.php?act=psearch&pid=120D978
OChem	30668	http://www.ocheminc.com/index.php?act=psearch&pid=120D978
Sigma-Aldrich	1188006_USP	https://www.sigmaaldrich.com/catalog/product/usp/1188006?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech	S017462	http://www.sinfoobiotech.com/product/1020860
Smolecule	S525960	http://www.smolecule.com/products/s525960
THE BioTek	bt-267833	https://www.thebiotek.com/product/inhibitors/bt-267833
Yuhao Chemical	LL0492	http://www.chemyuhao.com/120-97-8.html
abcr GmbH	AB547847	http://www.abcr.com/shop/en/AB547847
iChemical	EBD45291	http://www.ichemical.com/chemicals/cas-120-97-8
mcule	MCULE-4570158631	https://mcule.com/MCULE-4570158631/

PubMed

Title	Date	PubMed
Long-term management of a glaucomatous eye in a dog treated with medical therapy alone.	2001 Dec	11789611
Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV.	2003 Mar 10	12617904
Carbonic anhydrase inhibitors are specific openers of skeletal muscle BK channel of K+-deficient rats.	2004 Apr	14766795
Carbonic anhydrase inhibitors: N-(p-sulfamoylphenyl)-alpha-D-glycopyranosylamines as topically acting antiglaucoma agents in hypertensive rabbits.	2004 Jan 5	14684332
Benzolamide is not a membrane-impermeant carbonic anhydrase inhibitor.	2004 Jun	15499999
Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides.	2005 Sep 1	16039848
Carbonic anhydrase inhibitors ameliorate the symptoms of hypokalaemic periodic paralysis in rats by opening the muscular Ca2+-activated-K+ channels.	2006 Jan	16368240
Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs.	2006 Mar 23	16539401
Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.	2006 Nov 30	17125255
The development of topically acting carbonic anhydrase inhibitors as anti-glaucoma agents.	2007	17504129
Carbonic anhydrase inhibitors. DNA cloning, characterization, and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and sulfamate inhibitors.	2007 Jan 25	17228881
The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents.	2008	18336310
Treatment for periodic paralysis.	2008 Jan 23	18254068
Carbonic anhydrase inhibitors. Sulfonamide diuretics revisited--old leads for new applications?	2008 Jul 21	18600270
QSAR studies for the inhibition of the transmembrane carbonic anhydrase isozyme XIV with sulfonamides using PRECLAV software.	2009 Apr	18830873
Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.	2009 May 14	19338333
Evaluation of the therapeutic potential of carbonic anhydrase inhibitors in two animal models of dystrophin deficient muscular dystrophy.	2009 Nov 1	19648295

Sample Use Guides

In Vivo Use Guide

Initial dose: 50 mg twice daily.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Name

Type

Language

DICHLORPHENAMIDE

Common Name

English

DICHLORPHENAMIDE [USP IMPURITY]

Common Name

English

diclofenamide [INN]

Common Name

English

DICLOFENAMIDE [JAN]

Common Name

English

DARANIDE

Brand Name

English

DICLOFENAMIDE

Official Name

English

DICHLORPHENAMIDE [ORANGE BOOK]

Common Name

English

DICHLORPHENAMIDE [USP-RS]

Common Name

English

Diclofenamide [WHO-DD]

Common Name

English

DICHLORPHENAMIDE [MI]

Common Name

English

DICHLORPHENAMIDE [USP MONOGRAPH]

Common Name

English

DICHLORPHENAMIDE [HSDB]

Common Name

English

1,3-BENZENEDISULFONAMIDE, 4,5-DICHLORO-

Systematic Name

English

DICLOFENAMIDE [MART.]

Common Name

English

4,5-DICHLORO-M-BENZENEDISULFONAMIDE

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000175517